The Risks and Long-Term Affects of Psychiatric Drugs

Psychiatric drugs are commonly prescribed for depression, anxiety, insomnia, bipolar disorder, psychosis, ADHD, and other conditions. While these drugs can provide meaningful benefits for some individuals, long-term use may also carry significant risks that are not always fully understood or discussed when treatment begins. Some adverse effects develop shortly after starting a drug, while others may emerge gradually after months or years of use. Certain effects are dose-dependent, some are associated with prolonged exposure, and others may persist after a drug has been discontinued. Not everyone experiences these problems, and the risks vary considerably depending on the specific drug, dosage, duration of use, individual physiology, underlying health conditions, and interactions with other substances. Understanding these potential risks is an important part of informed consent, ongoing treatment decisions, and responsible deprescribing. 1. Antidepressants Drug classes: SSRIs, SNRIs, tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), and atypical antidepressants. Common examples include sertraline (Zoloft), fluoxetine (Prozac), escitalopram (Lexapro), venlafaxine (Effexor), duloxetine (Cymbalta), amitriptyline (Elavil), mirtazapine (Remeron), bupropion (Wellbutrin), and trazodone. Potential side effects and risks include:

• Sexual dysfunction: Reduced libido, genital numbness, erectile difficulties, delayed orgasm, and inability to achieve orgasm. In some cases, sexual dysfunction persists after discontinuation, a condition known as post-SSRI sexual dysfunction (PSSD).
• Emotional blunting: Reduced ability to experience pleasure, excitement, sadness, affection, or other emotions.
• Weight changes: Weight gain is associated with several antidepressants, although effects differ by drug and individual.
• Metabolic changes: Changes in appetite, weight, and potentially glucose regulation.
• Sleep disturbances: Insomnia, vivid dreams, nightmares, excessive sleepiness, and disrupted sleep architecture.
• Cardiovascular effects: Increased blood pressure, palpitations, changes in heart rate, and, with certain drugs, QT prolongation or other rhythm disturbances.
• Gastrointestinal problems: Nausea, diarrhea, constipation, indigestion, and changes in bowel habits.
• Excessive sweating: Night sweats and increased perspiration.
• Movement-related symptoms: Tremor, restlessness, bruxism, and occasionally akathisia or other movement disorders.
• Hyponatremia: Abnormally low sodium levels, particularly in older adults.
• Increased bleeding risk: Especially with SSRIs and SNRIs, and when combined with NSAIDs or anticoagulants.
• Bone health concerns: Observational studies associate some antidepressants with increased fracture risk, although causation is not fully established.
• Mania or hypomania: Particularly in susceptible individuals with bipolar disorder.
• Seizures: An uncommon but important risk with certain antidepressants, especially at higher doses or in susceptible individuals.
• Suicidal thoughts or behavioral changes: Particularly during treatment initiation or dose changes, with a well-established age-related warning for children, adolescents, and young adults.
• Physical dependence and withdrawal: The nervous system may adapt to prolonged exposure, leading to withdrawal symptoms if the drug is reduced or stopped.
• Protracted withdrawal symptoms: Some individuals report symptoms lasting months or longer after discontinuation.

2. Benzodiazepines Examples: Alprazolam (Xanax), clonazepam (Klonopin/Rivotril), lorazepam (Ativan), diazepam (Valium), and temazepam (Restoril). Potential side effects and risks include:

• Physical dependence, sometimes developing within weeks of regular use.
• Tolerance, with reduced effects over time.
• Rebound anxiety and insomnia.
• Memory impairment and difficulties learning new information.
• Reduced concentration, alertness, and processing speed.
• Sedation, fatigue, and daytime drowsiness.
• Impaired coordination, balance, and reaction time.
• Increased risk of falls, fractures, and motor vehicle accidents.
• Emotional blunting and depressive symptoms.
• Paradoxical agitation, irritability, aggression, or disinhibition.
• Respiratory depression, particularly when combined with opioids, alcohol, or other sedatives.
• Increased overdose risk when combined with other central nervous system depressants.
• Severe withdrawal reactions, including panic, perceptual disturbances, tremor, and seizures.
• Potentially prolonged neurological symptoms following discontinuation, sometimes described as benzodiazepine-induced neurological dysfunction (BIND).
• Associations with dementia in observational research, although a causal relationship has not been established.

Important: Abrupt discontinuation after physical dependence has developed can cause life-threatening withdrawal. 3. Antipsychotics Examples: Quetiapine (Seroquel), olanzapine (Zyprexa), risperidone (Risperdal), aripiprazole (Abilify), haloperidol (Haldol), and clozapine (Clozaril). Potential side effects and risks include:

• Tardive dyskinesia: Potentially persistent involuntary movements affecting the face, tongue, jaw, trunk, or limbs.
• Drug-induced parkinsonism: Tremor, stiffness, slowed movement, and changes in walking.
• Akathisia: Intense inner restlessness and an urge to move.
• Dystonia: Involuntary muscle contractions or abnormal postures.
• Weight gain and obesity: Particularly with certain second-generation antipsychotics.
• Insulin resistance and type 2 diabetes.
• Dyslipidemia: Increased cholesterol or triglycerides.
• Metabolic syndrome.
• Cardiovascular complications: Orthostatic hypotension, QT prolongation, and rhythm disturbances with certain drugs.
• Sedation and cognitive slowing.
• Elevated prolactin: Potentially causing menstrual changes, breast changes, sexual dysfunction, or reduced bone density.
• Constipation and gastrointestinal hypomotility: Especially serious with clozapine.
• Neuroleptic malignant syndrome: A rare but potentially fatal reaction involving fever, rigidity, and autonomic instability.
• Blood disorders: Clozapine can cause severe neutropenia and requires specific monitoring.
• Withdrawal and rebound symptoms: Including insomnia, agitation, nausea, movement symptoms, and possible recurrence or rebound of psychotic symptoms.
• Increased mortality in older adults with dementia-related psychosis: Reflected in regulatory boxed warnings.

Some movement disorders can continue after the drug is stopped. 4. Mood Stabilizers Examples: Lithium, valproate/divalproex (Depakote), carbamazepine (Tegretol), and lamotrigine (Lamictal). These drugs differ substantially in their mechanisms and adverse-effect profiles. Potential side effects and risks include:

• Kidney impairment: Particularly associated with long-term lithium use, including reduced kidney function and nephrogenic diabetes insipidus.
• Thyroid dysfunction: Lithium can contribute to hypothyroidism and thyroid enlargement.
• Weight gain: Especially with lithium and valproate.
• Tremor: Common with lithium and some anticonvulsant mood stabilizers.
• Cognitive effects: Mental slowing, reduced concentration, and memory complaints.
• Gastrointestinal disturbances: Nausea, diarrhea, vomiting, and abdominal discomfort.
• Liver injury: A potentially serious risk with valproate and carbamazepine.
• Pancreatitis: A rare but potentially life-threatening complication of valproate.
• Blood disorders: Including low platelet counts, low white blood cell counts, and rare severe blood disorders.
• Hormonal and reproductive effects: Valproate has been associated with menstrual irregularities and polycystic ovary syndrome.
• Birth defects and developmental risks: Particularly important with valproate exposure during pregnancy.
• Bone health concerns: Certain anticonvulsants can adversely affect bone metabolism with prolonged use.
• Serious skin reactions: Including Stevens–Johnson syndrome and toxic epidermal necrolysis, especially with lamotrigine and carbamazepine.
• Drug interactions: Some mood stabilizers interact significantly with other drugs and can alter blood concentrations.
• Toxicity: Lithium has a narrow therapeutic range, making dehydration, kidney changes, and certain drug interactions particularly important.
• Rebound or recurrence after discontinuation: Abrupt lithium discontinuation can increase the risk of mood episode recurrence.

Long-term lithium treatment generally requires monitoring of kidney function, thyroid function, and blood lithium levels. 5. Stimulants Used for ADHD Examples: Amphetamine/dextroamphetamine (Adderall), lisdexamfetamine (Vyvanse), methylphenidate (Ritalin), and dexmethylphenidate (Focalin). Potential side effects and risks include:

• Increased heart rate and blood pressure.
• Palpitations and cardiovascular strain.
• Appetite suppression and unintended weight loss.
• Sleep disturbances and chronic insomnia.
• Anxiety, agitation, irritability, and restlessness.
• Headaches and gastrointestinal complaints.
• Increased sweating and dry mouth.
• Bruxism, tics, or exacerbation of existing movement symptoms.
• Emotional changes, including mood instability in some individuals.
• Rare stimulant-induced psychosis or mania.
• Peripheral vasculopathy, including Raynaud's phenomenon.
• Misuse, addiction, and physical dependence risks.
• Tolerance to certain effects in some individuals.
• Fatigue, depressed mood, or sleep changes after discontinuation.

Long-term effects on cardiovascular health and other outcomes continue to be studied. Risk depends on the drug, dose, existing medical conditions, and individual susceptibility. 6. Z-Drugs and Other Prescription Sleep Drugs Examples: Zolpidem (Ambien), zopiclone (Imovane), eszopiclone (Lunesta), and zaleplon (Sonata). Potential side effects and risks include:

• Tolerance and physical dependence.
• Rebound insomnia after discontinuation.
• Daytime sedation and impaired alertness.
• Memory disturbances and confusion.
• Dizziness, impaired balance, and falls.
• Reduced coordination and driving impairment.
• Unusual dreams, hallucinations, or behavioral changes.
• Complex sleep behaviors, including sleepwalking, sleep-eating, or sleep-driving.
• Increased impairment when combined with alcohol, opioids, or other sedatives.
• Withdrawal symptoms following abrupt discontinuation, with severe reactions possible in some circumstances.

The FDA has issued boxed warnings about potentially fatal complex sleep behaviors involving zolpidem, eszopiclone, and zaleplon. 7. Other Psychiatric Drugs Additional drugs sometimes used in psychiatric treatment include gabapentin (Neurontin), pregabalin (Lyrica), buspirone (BuSpar), hydroxyzine (Atarax/Vistaril), and propranolol (Inderal). These drugs have different mechanisms, so their risks should not be treated as interchangeable. Potential concerns include:

• Gabapentin and pregabalin: Dizziness, sedation, cognitive difficulties, edema, weight gain, physical dependence, withdrawal symptoms, and increased respiratory-depression risk when combined with certain sedatives.
• Buspirone: Dizziness, nausea, headaches, and restlessness. Its dependence risk is substantially lower than that of benzodiazepines.
• Hydroxyzine: Sedation, dry mouth, constipation, anticholinergic effects, and QT prolongation in susceptible individuals.
• Propranolol: Fatigue, dizziness, low blood pressure, slowed heart rate, sleep disturbances, and possible worsening of certain respiratory conditions. Abrupt discontinuation after regular use can cause cardiovascular rebound effects.

8. Risks Associated With Taking Multiple Psychiatric Drugs Taking several psychiatric drugs simultaneously, commonly referred to as polypharmacy, may increase the likelihood of adverse effects and drug interactions. Potential concerns include additive sedation, cognitive impairment, falls, cardiovascular complications, metabolic burden, sexual dysfunction, and difficulty identifying which drug is responsible for a particular symptom. Specific combinations can create additional hazards, including serotonin syndrome from certain serotonergic combinations, respiratory depression from multiple sedating drugs, and QT prolongation from drugs that affect cardiac electrical activity. Polypharmacy may sometimes be clinically appropriate, but regular reviews are important to assess whether each drug continues to provide sufficient benefit to justify its risks. 9. Physical Dependence, Withdrawal, and Persistent Symptoms One of the most important considerations in long-term psychiatric drug use is the possibility of physiological adaptation. With repeated exposure, the nervous system may adjust to a drug's effects. When the dose is reduced or discontinued, these adaptations may contribute to withdrawal symptoms. Physical dependence is not the same as addiction. A person can become physically dependent on a prescribed drug while taking it exactly as directed, without craving it, misusing it, or displaying compulsive drug-seeking behavior. Potential withdrawal symptoms across different drug classes include:

• Anxiety, panic, agitation, and irritability.
• Insomnia and disturbed sleep.
• Dizziness, vertigo, and balance problems.
• Headaches and pressure sensations.
• Nausea, diarrhea, and appetite changes.
• Tremors, muscle twitching, and restlessness.
• Sensory disturbances, including tingling, burning, and electric-shock sensations.
• Sweating and temperature-regulation difficulties.
• Palpitations and changes in autonomic symptoms.
• Cognitive difficulties and poor concentration.
• Depersonalization or derealization.
• Depressed mood and emotional instability.
• Rebound symptoms or recurrence of the original condition.

Some individuals experience prolonged or persistent symptoms following discontinuation. These experiences warrant clinical attention, although the mechanisms, prevalence, and duration are not fully understood across all drug classes. Withdrawal symptoms can also resemble a recurrence of the original condition, making careful assessment particularly important. 10. The Importance of Informed Consent and Regular Drug Reviews People taking psychiatric drugs should have access to clear, balanced information about potential benefits, adverse effects, drug interactions, recommended monitoring, and the possibility of withdrawal. Long-term treatment should be periodically reviewed rather than automatically continued without reassessment. Such reviews may include physical health monitoring, evaluation of ongoing benefit, consideration of non-drug supports, and discussion of whether continued treatment remains appropriate. For those who wish to discontinue, gradual, individualized tapering is generally preferable to abrupt cessation. The appropriate approach varies by drug, treatment history, and individual response. Some people require smaller reductions and longer intervals between changes. Important: This document is not intended to encourage anyone to abruptly stop psychiatric drugs. Rapid discontinuation can cause serious complications, including seizures with certain drugs and recurrence of severe psychiatric symptoms. Decisions about tapering should be individualized and made with appropriate clinical support. References and Further Reading The following sources provide regulatory safety information, clinical guidance, and research relevant to the risks discussed above. 1. NICE — Depression in Adults: Treatment and Management (NG222). Includes guidance on antidepressant adverse effects, withdrawal, and individualized tapering. https://www.nice.org.uk/guidance/ng222/chapter/Recommendations 2. FDA — Benzodiazepine Drug Class Boxed Warning. Addresses physical dependence, addiction, withdrawal, seizures, and overdose risks. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class 3. Royal College of Psychiatrists — Stopping Antidepressants. Explains antidepressant withdrawal and approaches to gradual discontinuation. https://www.rcpsych.ac.uk/mental-health/treatments-and-wellbeing/stopping-antidepressants 4. Horowitz and Taylor (2019) — Tapering of SSRI Treatment to Mitigate Withdrawal Symptoms. The Lancet Psychiatry. https://doi.org/10.1016/S2215-0366(19)30032-X 5. Davies and Read (2019) — A Systematic Review into the Incidence, Severity and Duration of Antidepressant Withdrawal Effects. Addictive Behaviors. https://doi.org/10.1016/j.addbeh.2018.08.027 6. FDA — Z-Drug Boxed Warning for Complex Sleep Behaviors. https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-boxed-warning-risk-serious-injuries-caused-sleepwalking-certain-prescription-insomnia-medicines 7. FDA — Serious Breathing Problems With Gabapentin and Pregabalin. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin 8. FDA — Prescription Stimulants: Misuse, Abuse, Addiction, and Overdose Warnings. https://www.fda.gov/drugs/drug-safety-and-availability/prescription-stimulants-drug-safety-communication-fda-updating-warnings-improve-safe-use-prescription 9. MedlinePlus — Lithium. Includes information on adverse effects, interactions, and monitoring. https://medlineplus.gov/druginfo/meds/a681039.html 10. MedlinePlus — Valproic Acid. Includes liver, pancreatic, reproductive, and other safety warnings. https://medlineplus.gov/druginfo/meds/a682412.html 11. MedlinePlus — Antipsychotic Drug Information. Drug-specific adverse effects and safety warnings can be found through its drug information database. https://medlineplus.gov/druginformation.html 12. FDA — MedWatch. Reporting suspected adverse drug reactions and safety problems. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program Final Thoughts Psychiatric drugs can affect far more than mood, anxiety, or sleep. Depending on the drug, they may influence neurological functioning, metabolism, cardiovascular health, hormones, cognition, movement, sexual functioning, and other bodily systems. Although many individuals tolerate these drugs and experience meaningful benefits, others develop adverse effects that significantly affect their health and quality of life. Some risks are well established, while others remain under investigation. The goal of sharing this information is not to create fear, but to promote informed decision-making, careful monitoring, recognition of adverse effects, and safer approaches to deprescribing. At Taper Community, we believe that individuals deserve accurate information, compassionate support, and the opportunity to make informed decisions about their own health. --- Disclaimer: This resource is for educational purposes only and is not a substitute for individualized medical advice. Not every risk listed applies to every drug or every person. Some adverse effects are uncommon or rare, and some reported long-term associations have not been established as causal.